Event Gaps: DeepSeek's picks for 2026-10-09
DeepSeek picked HUM, TEVA, T, VZ, AAPL for a 1-day horizon. Intraday alpha vs SPY: -0.88%. Picks with positive alpha: 20%.
| Experiment | Event Gaps |
|---|---|
| Model | DeepSeek |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -0.88% |
| Picks with positive alpha | 20% |
| Benchmark return | +0.22% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HUM | -0.40% | -0.40% | 75% | -0.62% | No | |
| 2 | TEVA | -1.22% | -1.22% | 70% | -1.44% | No | |
| 3 | T | -0.96% | +0.96% | 72% | +0.74% | Yes | |
| 4 | VZ | -0.21% | +0.21% | 68% | -0.01% | No | |
| 5 | AAPL | +2.84% | -2.84% | 65% | -3.06% | No |
The model's market view
US equities enter the window with sharp idiosyncratic dispersion. The SpaceX spectrum deal has triggered a structural selloff in telecom carriers, while CMS Medicare Advantage star-rating changes are creating extreme movers in managed care. Apple faces demand-side pressure from component order cuts. The window spans a weekend and ends Monday morning, so Friday afternoon positioning, weekend news flow, and Monday pre-market activity will dominate. Momentum in the most affected names may persist as analysts revise estimates.
Why each pick
HUM
Humana surged ~14-17% in after-hours and pre-market trading after CMS awarded its largest Medicare Advantage contract (H5216, covering 2M+ members) a 4-star rating for 2027, up from 3.5 stars, restoring bonus eligibility. The catalyst occurred on Oct 8 after close, but the move is still being digested. Analyst upgrades (Baird to Outperform, $596 PT; Oppenheimer to $475 PT) followed on Oct 9 and could fuel further gains through Monday. The main risk is profit-taking after the sharp initial pop, but positive estimate revisions and the structural improvement in bonus revenue support continued upside from Friday mid-morning to Monday mid-morning.
TEVA
Teva Pharmaceutical Industries received FDA approval for Weltruza (olanzapine LAI), a once-monthly injectable for schizophrenia, on October 9, 2026. The stock jumped ~6.6% intraday on the news. The approval is a material positive catalyst that expands Teva's long-acting injectable portfolio and is expected to launch in the US in the coming weeks. The initial move has occurred, but continued analyst recognition and commercial launch anticipation could support further gains through Monday. Risks include profit-taking and the stock already trading near 52-week highs.
T
AT&T dropped ~9% at the open on October 9 after SpaceX announced a definitive agreement on October 8 to acquire a nationwide 800MHz low-band spectrum portfolio from Grain Management, positioning Starlink to enter the US mobile market. The competitive threat is structural and ongoing. Analysts downgraded price targets (Scotiabank cut T to $26.50 from $27.50). The initial selloff has occurred, but the market is likely to continue repricing telecom carriers as the implications for churn, pricing, and capital spending become clearer. The window from Friday mid-morning to Monday mid-morning may see continued downside as the market digests the competitive threat.
VZ
Verizon fell ~6-7% on October 9 following the SpaceX spectrum deal, which signals a credible new entrant into the US wireless market. Verizon has invested heavily in terrestrial spectrum and network infrastructure, and the threat of Starlink mobile services could pressure pricing and subscriber growth. Scotiabank lowered its price target to $50 from $51.50. The initial drop has occurred, but the structural nature of the competitive threat suggests continued downside as the market assesses long-term implications. The window captures Friday afternoon through Monday morning, a period likely to see further analyst revisions and negative sentiment.
AAPL
Apple fell ~1.7-2% in pre-market trading on October 9 after Nikkei Asia reported that the company asked suppliers to cut component orders for the iPhone 18 Pro and iPhone 18 Pro Max by 15-20% for October due to soft demand and rising memory chip costs. The report is a negative demand signal for Apple's premium handset lineup. While the initial drop has occurred, the demand concerns are likely to persist and could weigh on the stock through Monday as analysts assess the implications for Q4 iPhone revenue. Risks include a broader market rebound or Apple-specific buying support, but the near-term catalyst is negative.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| GPT-6 | HUM, CCI, TMUS, T, DAL | +0.16% | 20% |
| Muse Spark 1.1 | DAL, TMUS, T, VZ, LEVI | -0.40% | 40% |
| Gemini 1.5 Pro | DAL, AAPL, HUM, CEG, AMD | +0.17% | 40% |
| Perplexity | HUM, TEVA, DAL, AAPL, LITE | -2.50% | 0% |
| Grok 4.5 | DAL, VZ, TMUS, JPM, GS | +0.47% | 60% |
| Claude Sonnet 5.5 | HUM, TMUS, LITE, CCI, DAL | -2.52% | 0% |
Written up on ForecastNest Insights: Event Gaps: DeepSeek's picks for 2026-10-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.